Ptc Therapeutics (PTCT) Cost of Revenue (2017 - 2026)

Ptc Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $28.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 117.91% year-over-year to $28.0 million; the TTM figure through Mar 2026 stood at $62.2 million (up 11.99% YoY), while the FY2025 annual figure was $47.0 million, down 18.09% from the prior year.
• Cost of Revenue was $28.0 million for Q1 2026 at Ptc Therapeutics, up from $7.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $29.1 million in Q4 2023 to a low of $7.0 million in Q4 2025.
• Historically, Cost of Revenue has averaged $14.3 million across 5 years, with a median of $12.9 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue jumped 167.31% in 2023, then plunged 57.32% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $10.9 million in 2022, then soared by 167.31% to $29.1 million in 2023, then sank by 44.08% to $16.3 million in 2024, then slumped by 57.32% to $7.0 million in 2025, then surged by 303.28% to $28.0 million in 2026.
• The last three Cost of Revenue figures came in at $28.0 million (Q1 2026), $7.0 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.